Drug intelligence / Profile preview

anti-α5β8 integrin antibody

Development stage
Preclinical
Lead developer
Northwestern University
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Anti-α5β8 integrin antibody is a monoclonal antibody designed to target and inhibit the α5β8 integrin complex. In the context of glioblastoma (GBM) research, this integrin has been identified as a critical component in the activation and release of Transforming Growth Factor-beta (TGFβ) within the tumor microenvironment. By blocking α5β8, the antibody prevents the immunosuppressive effects of TGFβ, thereby promoting the accumulation of germinal-center-like B cells and enhancing the anti-tumor activity of T cells. Preclinical studies in murine glioma models have shown that treatment with an anti-α5β8 antibody, particularly in combination with PD-1 blockade, can increase the infiltration of proliferating B-cells and significantly extend survival. This approach highlights a potential therapeutic strategy for modulating the immune landscape of 'cold' tumors like glioblastoma.

Other names
anti-a5b8 integrin antibodyanti-a-5b8 integrin antibodyanti-a 5b8 integrin antibody
02

Targets

αVβ8 (Integrin alpha V beta 8)

Beyond the preview

Go deeper on anti-α5β8 integrin antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-α5β8 integrin antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call